Is Axsome Therapeutics, Inc. (0HKF.L) a Buy, Sell, or Hold?
LSE : 0HKF.L
Axsome Therapeutics, Inc.
$240.72 USD
-$0.99 (-0.41%)
- Volume
- 1.36K
- Average Volume
- 562
- Market Capitalization
- $12.12B
- P/E Ratio
- -64.61
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $243.56
- Year Low
- $55.64
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.39
Company Overview
LSE
Herriot Tabuteau
Biotechnology
Healthcare
0HKF.L
712
US
USD
Liquidity Metrics
4.03
1.39
1.32
0.69
0.00
Sales & Valuation
$638.5M
17.51
226.04
-174.69
-1.39
Profitability
-$3.68
-$183.17M
-26.59%
-26.66%
-260.01%
-26.39%
P/E Metrics
-64.61
-1.44
-1.44
Analyst Price Target & Rating
1/5
21 Analysts
%
Financial Health Scores
8.71
4/9
$172M
$713.61M
$659.02M
-$189.75M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Herriot Tabuteau | Founder, Chairman, Chief Executive Officer & President |
| Hunter Murdock | General Counsel & Secretary |
| Mark L. Jacobson | Chief Operating Officer |
| Darren Opland | Director of Corporate Communications |
| Ari Maizel | Chief Commercial Officer |
| Nick Pizzie | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Axsome Therapeutics, Inc. (LSE:0HKF.L) Stock
Axsome Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative treatments for central nervous system (CNS) disorders, primarily focusing on the United States market. Its pipeline includes AXS-05, a therapeutic candidate for major depressive disorder and treatment-resistant depression, which is also currently in Phase III clinical trials for Alzheimer's disease agitation and has completed Phase II studies for smoking cessation. The company is also advancing AXS-07, an experimental, rapidly absorbed, oral medication with a multi-mechanistic profile, which has successfully concluded two Phase III trials for the acute treatment of migraine. Another key asset is AXS-12, a selective and potent norepinephrine reuptake inhibitor, presently in Phase III dev ... elopment for narcolepsy. Furthermore, AXS-14, an investigational oral medicine, is undergoing Phase III trials for fibromyalgia. Axsome Therapeutics maintains a research collaboration with Duke University to further evaluate AXS-05 for smoking cessation. The company was founded in 2012 and is headquartered in New York, New York.
Frequently Asked Questions
-
What is the current Axsome Therapeutics, Inc. (0HKF.L) stock price?
-
Axsome Therapeutics, Inc.(LSE:0HKF.L) stock price is $240.72 in the last trading session. During the trading session, 0HKF.L stock reached the peak price of $243.56 while $55.64 was the lowest point it dropped to. The percentage change in 0HKF.L stock occurred in the recent session was --0.41% while the dollar amount for the price change in 0HKF.L stock was -$0.99.
-
0HKF.L's industry and sector of operation?
-
The LSE listed 0HKF.L is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of 0HKF.L?
-
Herriot Tabuteau | Founder, Chairman, Chief Executive Officer & President
Hunter Murdock | General Counsel & Secretary
Mark L. Jacobson | Chief Operating Officer
Darren Opland | Director of Corporate Communications
Ari Maizel | Chief Commercial Officer -
How many employees does 0HKF.L have?
-
Number of 0HKF.L employees currently stands at 712. 0HKF.L operates from 22 Cortlandt Street, New York City, NY 10007, US.
-
Link for 0HKF.L official website?
-
Official Website of 0HKF.L is: https://www.axsome.com
-
How do I contact 0HKF.L?
-
0HKF.L could be contacted at phone #212 332 3241 and can also be accessed through its website. 0HKF.L operates from 22 Cortlandt Street, New York City, NY 10007, US.
-
How many shares of 0HKF.L are traded daily?
-
The average number of 0HKF.L shares traded daily for last 3 months was 562.
-
What is the market cap of 0HKF.L currently?
-
The market value of 0HKF.L currently stands at $12.12B with its latest stock price at $240.72